Therapy‐related myeloid neoplasms after treatment for ovarian cancer: A retrospective single‐center case series

• Published in: The journal of obstetrics and gynaecology research 2024-07, Vol.50 (7), p.1148-1154
• Main Authors: Matsuoka, Ayumu, Tate, Shinichi, Nishikimi, Kyoko, Otsuka, Satoyo, Usui, Hirokazu, Tajima, Shinya, Habu, Yuji, Nakamura, Natsuko, Okuya, Rie, Katayama, Eri, Shozu, Makio, Inaba, Yosuke, Koga, Kaori
• Format: Article
• Language: English
• Subjects: acute myeloid leukemia; Antineoplastic drugs; Bevacizumab; Cancer therapies; Carboplatin; Chemotherapy; Cytology; Gemcitabine; Irinotecan; Leukemia; Medical prognosis; Myelodysplastic syndrome; Myelodysplastic syndromes; Ovarian cancer; Paclitaxel; Pancytopenia; Patients; therapy‐related neoplasms; Thrombocytopenia; Tumors
• ISSN: 1341-8076; 1447-0756; 1447-0756
• DOI: 10.1111/jog.15954

Objective Therapy‐related myeloid neoplasms (t‐MNs) are often fatal and arise as late complications of previous anticancer drug treatment. No single‐center case series has examined t‐MNs in epithelial ovarian cancer (EOC). Methods All patients with EOC treated at Chiba University Hospital between 2000 and 2021 were included. We retrospectively analyzed the characteristics, clinical course, and outcomes of patients who developed t‐MNs. Results Among 895 cases with EOC, 814 cases were treated with anticancer drugs. The median follow‐up period was 45 months (interquartile range, 27–81) months. Ten patients (1.2%) developed t‐MNs (FIGO IIIA in one case, IIIC in three, IVA in one, and IVB in five). Nine patients were diagnosed with myelodysplastic syndrome and one with acute leukemia. One patient with myelodysplastic syndrome developed acute leukemia. The median time from the first chemotherapy administration to t‐MN onset was 42 months (range, 21–94 months), with t‐MN diagnoses resulting from pancytopenia in four cases, thrombocytopenia in three, and blast or abnormal cell morphology in four. The median number of previous treatment regimens was four (range, 1–7). Paclitaxel + carboplatin therapy was administered to all patients, gemcitabine and irinotecan combination therapy to nine, bevacizumab to eight, and olaparib to four. Six patients received chemotherapy for t‐MN. All patients died (eight cancer‐related deaths and two t‐MN‐related deaths). None of the patients was able to restart cancer treatment. The median survival time from t‐MN onset was 4 months. Conclusions Patients with EOC who developed t‐MN were unable to restart cancer treatment and had a significantly worse prognosis.